

The Pharma Legal Handbook

Czech Republic

Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms · Cannabinoid Drugs, Medicinal Cannabis and Opioid Drugs

Czech Republic

The Pharma Legal Handbook answers essential questions about this environment for pharmaceuticals in Czech Republic. It is a must have for any company operating in the country or looking to enter the market.

Prepared in association with PRK Partners, one of the leading law firms in the Czech Republic, it should answer any questions linked to Regulation, Pricing, Clinical and Preclinical Trials, Marketing, Manufacturing, Trademarks and Patents.

PharmaBoardroom is not responsible for any mistakes contained within this publication. For specific advice on any legal issue, please contact a qualified professional.

Copyright: All rights reserved. No part of this publication may be reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this report, neither PharmaBoardroom nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors.

* THIS REPORT WAS ORIGINALLY PUBLISHED IN SEPTEMBER 2019 AND THE INFORMATION CONTAINED WITHIN IS SUBJECT TO CHANGE.

P / R / K

ATTORNEYS AT LAW

For more than 25 years PRK Partners has been providing top-tier, comprehensive legal services in all areas of law – always at the highest professional level. The company's offices in Prague, Ostrava and Bratislava, as well as its specialized teams of legal practitioners and tax advisors, allow PRK Partners to offer solutions to any kind of legal issues, providing an international point of view and in-depth knowledge of the respective local legal system.

PRK Partners is a leading full-service law firm with a well-earned reputation of excellence in Central and Eastern Europe. We worked on many of the region's largest and most complex transactions. The firm puts emphasis on the highest standards of quality, efficiency and flexibility in its advisory services, which are tailored to the specific requirements of each client. Our team is composed of more than 100 professionals with international education and experience. PRK Partners is a holder of significant international and national awards, such as **Law Firm of the Year 2016** by Chambers & Partners, repeatedly **Best Law Firm of the Year** (national competitions organized by epravo.cz), **Law Firm of the Year 2012 for the Central European Region** (and consistently ranked among the top 6 finalists every year) by top UK legal magazine, The Lawyer, as well as by Legal 500 and International Financial Law Review.

The firm has a strong commitment to corporate social responsibility and pro bono work.

PRK Partners is the exclusive member firm in the Czech Republic for Lex Mundi, the world's leading network of independent law firms, with in-depth experience in 100+ countries worldwide. The firm is also a member of the Celia Alliance, AFI (Association for Foreign Investment) and CVCA (the Czech Private Equity and Venture Capital Association).



THE AUTHORS



**MGR. MONIKA
MAŠKOVÁ**

Monika Mašková is an attorney at law and, since 2018, also partner at PRK Partners.

Monika specializes in providing legal services to pharmaceutical, healthcare and food-processing industries. During her legal practice, particularly in the pharmaceutical sector, she gained valuable and in-depth experience in regulatory and compliance processes, as well as other key aspects, such as M&As in the pharmaceutical industry, R&D and personal data protection, which is becoming more and more relevant nowadays. Monika also assists major clients in other regulated industry sectors, such as medical device and cosmetics manufacturers and television broadcast operators.

Monika obtained her Master's degree (Mgr.) in law from the Faculty of Law of Charles University in Prague in 2005, when she joined PRK Partners. She furthered her legal studies at the University of Passau in Germany and at Tsukuba University in Japan. In 2008 – 2009 Monika worked as an in-house lawyer in the project finance department of a leading Czech bank, and in 2012 – 2013 she acted as legal counsel at a major pharmaceutical company, where she worked closely with the management and handled all legal matters of the company.

In addition to her native Czech, Monika is fluent in English and German.

Monika has contributed articles to leading publications, such as Mergers and Acquisitions in Europe: Selected Issues and Jurisdictions (Comparative Law Yearbook of International Business, Wolters Kluwer, 2011) and PLC Cross-border Doing Business in Handbook.

Partner, PRK Partners Prague
e-mail: monika.maskova@prkpartners.com
tel: +420 221 430 111



**JUDR. ING.
MICHAL
MATĚJKA**

Michal Matějka is a new partner at PRK Partners specializing in IT law, intellectual and industrial property law (including IP in Pharma sector), commercial contract law, international trade and related dispute resolution.

Before joining PRK Partners, Michal worked almost 17 years at Baker & McKenzie's Prague office.

Michal graduated from the Faculty of Law of Charles University in Prague and the Faculty of International Relations at the University of Economics in Prague and passed the bar to become an attorney at law in 2008. In 2018 Michal obtained his qualification as an established European lawyer authorized to provide legal services within the territory of Slovakia.

Michal has extensive experience in representing global and multinational clients in judicial, contractual and regulatory matters. He regularly lectures on ICT and intellectual property law at the Faculty of Information Technology of Czech Technical University (ČVUT) and the Faculty of Law of Charles University in Prague. Michal is an expert for domain dispute resolution in UDRP proceedings and .cz domain disputes and the author of various scholarly publications and articles in specialist periodicals on topics in his practice areas.

Michal is fluent in Czech and English.

Partner, PRK Partners Prague
e-mail: michal.matejka@prkpartners.com
tel: +420 221 430 111

P / R / K

ATTORNEYS AT LAW



A Step Ahead



CHAMBERS
EUROPE
AWARDS
for Excellence
2014
WINNER

www.prkpartners.com

CONTENTS

01	REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW	Page 6
-----------	--	--------

02	PRECLINICAL AND CLINICAL TRIAL REQUIREMENTS	Page 14
-----------	--	---------

03	MARKETING, MANUFACTURING, PACKAGING AND LABELING ADVERTISING	Page 18
-----------	---	---------

04	TRADITIONAL MEDICINES AND OVER-THE-COUNTER PRODUCTS	Page 31
-----------	--	---------

05	PRODUCT LIABILITY	Page 37
-----------	--------------------------	---------

06	PATENTS AND TRADEMARKS	Page 41
-----------	-------------------------------	---------

07	REGULATORY REFORMS	Page 47
-----------	---------------------------	---------

08	CANNABINOID DRUGS, MEDICINAL CANNABIS AND OPIOID DRUGS	Page 50
-----------	---	---------

01

REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW

1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?

2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?

3. What are the steps to obtaining authorization to develop, test, and market a product?

4. What are the approximate fees for each authorization?

5. For how long are marketing authorizations/registrations valid? How are marketing authorizations/registrations renewed?

6. How does the authorization process differ between brand-name products and generic products? Are there differences for local manufacturers versus foreign-owned manufacturers?

7. How are combination products (drug + drug, drug + biologic, drug + device, biologic + device, drug + biologic + device) regulated?

8. How is compliance with regulation monitored and evaluated? Is the regulatory regime comparable with the U.S. Food and Drug Administration or the European Medicines Agency expectations and requirements?

9. What is the potential range of penalties for noncompliance?

10. Is there a national healthcare system? If so, how is it administered and funded?

11. How does the government (or public) healthcare system function with private sector healthcare?

12. Are prices of drugs and devices regulated and, if so, how?

13. How are drugs and devices used by patients paid for? What roles do public and private payers play?

14. Who dispenses drugs and devices to patients and how are those dispensers compensated?

15. What are the professional and legal responsibilities of those who dispense drugs and devices? What role do they play in providing patient care, information, and safety?

01 REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW

1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?

The main authorities with jurisdiction over drugs, biologicals and medical devices in the Czech Republic are the Ministry of Health and the State Institute for Drug Control. Along with these two main regulatory authorities, the following authorities also possess limited and specific jurisdiction over drugs, biologicals and/or medical devices: the Ministry of the Interior, Ministry of Justice, Ministry of Defence, Ministry of the Environment, Ministry of Agriculture, State Veterinary Administration, Institute for State Control of Veterinary Biologicals and Medicines, State Office for Nuclear Safety, Customs Authorities, District Veterinary Authorities and District Authorities.

2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?

The authorization, pricing and reimbursement of drugs, biologicals and medical devices is mainly regulated by the following acts (and related regulations):

- Act No. 378/2007 Coll., on Drugs, as amended (the “Act on Drugs”);
- Act No. 48/1997 Coll., on Public Health Insurance, as amended (the “Public Health Insurance Act”);
- Act No. 268/2014 Coll., on Medical Devices, as amended (the “Act on Medical Devices”); and
- Act No. 526/1990 Coll., on Prices, as amended.

3. What are the steps to obtaining authorization to develop, test, and market a product?

In order to conduct testing of drugs, which have not been registered yet, it is necessary to obtain a clinical trial authorization from the State Institute for Drug Control. For the testing of drugs, which have already been registered, it is sufficient to notify the State Institute for Drug Control of the clinical trial.

In order to introduce a drug to the market, it is necessary to obtain a registration (marketing authorization). There are three types of registrations: (i) National Registration, (ii) Mutual Recognition Procedure and (iii) Decentralized Procedure. National Registration authorizes the marketing of the product solely in the territory of the Czech Republic. The other two authorization types authorize the marketing of the product in other EEA states as well. In addition, the Centralized Procedure by the European Medicines Agency, which authorizes the product for all EEA states, can also be used. The requirement for a marketing authorization does not apply in a limited number of exceptions (drugs prepared in a pharmacy based on a prescription for an individual patient, drugs for research and development, etc.).

Manufacturers and distributors of drugs are required to obtain licenses from the State Institute for Drug Control. A manufacturing license is required also for importing drugs from non-EEA states. Distribution licenses issued by

EEA states are recognized in the Czech Republic provided that the distributor submits a notification to the State Institute for Drug Control.

4. What are the approximate fees for each authorization?

The approximate fees for each authorization are:

- Authorization of a clinical trial for a not yet registered drug: approx. EUR 1,750
- Authorization of a clinical trial for a registered drug: approx. EUR 800
- National Registration: approx. EUR 9,000 to approx. EUR 11,000
- Mutual Recognition Procedure: approx. EUR 11,000
- Decentralized Procedure: approx. EUR 16,800

For further details on fees please see: <http://www.sukl.eu/sukl/ust-29-version-19>

5. For how long are marketing authorizations/registrations valid? How are marketing authorizations/registrations renewed?

Marketing authorizations are valid for 5 years after the decision granting the authorization comes into force and effect. The State Institute for Drug Control may extend the validity of the authorization on the basis of an application submitted no later than nine months before the expiry of such authorization and a review of the risk-benefit balance of the drug. If the extension is approved by the State Institute for Drug Control, the authorization will last for an indefinite term.

6. How does the authorization process differ between brand-name products and generic products? Are there differences for local manufacturers versus foreign-owned manufacturers?

In general, the authorization process is the same for original and generic products. The only difference is that under certain circumstances results of preclinical and clinical trials do not have to be submitted in cases where the reference product has been registered in at least one other EEA member state for at least eight years.

The authorization process prescribed by law is the same for local manufacturers as well as foreign-owned manufacturers.

However, the applicants for the marketing authorization must have their residency or registered seat in the Czech Republic or in another EEA member state.

7. How are combination products (drug + drug, drug + biologic, drug + device, biologic + device, drug + biologic + device) regulated?

Under Czech law, both biologics and drugs are classified as drugs and are subject to the same regulation under the Act on Drugs, while medical devices are regulated separately under the Act on Medical Devices. There is no special regulation aimed at combination products. Therefore, any combination of drugs and biologics is regulated by the Act on Drugs. With respect to combinations of drugs/biologics and medical devices, the part consisting of a drug/biologic is regulated by the Act on Drugs and the part consisting of a medical device is regulated by the Act on Medical Devices, unless the part consisting of a medical device is fully integrated into the product and is for single use only, in which case the product as a whole is considered to be a drug and is regulated solely by the Act on Drugs.

8. How is compliance with regulations monitored and evaluated? Is the regulatory regime comparable with the U.S. Food and Drug Administration or the European Medicines Agency expectations and requirements?

The State Institute for Drug Control monitors compliance with the Act on Drugs and the performance of obligations imposed on the basis of its decisions and measures with respect to relevant subjects, including the manufacturers and distributors of drugs and medical devices. It also carries out inspections in order to ensure compliance with the requirements of GMP (good manufacturing practice), GDP (good distribution practice) and good clinical practice in the area of human pharmacy. The State Institute for Drug Control also operates and manages the pharmacovigilance system for drugs as well as medical devices and participates in the pharmacovigilance processes in the EU.

In general, the Czech regulatory regime can be deemed comparable with the one of the European Medicines Agency.

9. What is the potential range of penalties for noncompliance?

The range of penalties is dependent on the type of violation and whether it has been committed by a natural person or a legal entity/entrepreneur. The amounts of the penalties range from approx. EUR 390 to approx. EUR 780,000. Apart from financial penalties, a prohibition of activity (for up to two years) may be also imposed.

10. Is there a national healthcare system? If so, how is it administered and funded?

Yes, there is a national healthcare system in the Czech Republic. It is mainly regulated by the Public Health Insurance Act and is based on the principles of universal accessibility of healthcare and solidarity, mandatory health insurance, freedom to choose a health insurance company and a basic package of healthcare covered by the public health insurance.

Participation in the public healthcare insurance system is mandatory for every person with a permanent residency in the Czech Republic and every employee whose employer has a permanent residency or seat in the Czech Republic. The system is funded through mandatory monthly contributions by (i) employees and self-employed persons, (ii) employers and (iii) the state, which pays the insurance contributions for socially least-advantaged individuals, like children, students, pensioners, etc. Contributions are paid to individual health insurance companies (currently, seven health insurance companies hold the authorization to provide public health insurance in the Czech Republic, one health insurance company is owned by the Czech state). Health insurance companies are obliged to ensure healthcare is provided to their clients. They play a key role in the system of purchasing healthcare services by contracting with individual healthcare providers.

Czech legislation specifies the types of healthcare covered by the public health insurance system and the extent of such coverage; basically, the public health insurance system fully covers preventive medical examinations, diagnosis of diseases, and treatment of diseases as specified by applicable Czech law; it also determines the drugs and medical devices which are fully or partially covered by public health insurance and the respective conditions thereof.

In comparison with public health insurance, the share of private health insurance is rather negligible in the Czech Republic.